<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Amy Clausen

Recent Posts

MD Biosciences Expands Pre-clinical Inflammatory & Neuro Drug Research

Posted by Amy Clausen on Oct 5, 2009 11:51:00 AM

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009. The new location equips MD Biosciences with more lab space, allowing for increased capacity for in vitro services and product development and manufacturing to increase product offering.

Eddie Moradian, President of MD Biosciences states, "At MD Biosciences, we have always promised our clients that we will meet their needs now and in the future; our expansion ensures that commitment. We doubled our lab space so that we are able to provide 150 percent more services and increase product development by 130 percent in the coming year in comparison with the last.

Our relocation is just one step of many in the endeavor to continue to offer the highest quality services and products in assisting our customers in meeting their objectives. Future projections include adding more highly specialized scientists to our team and increasing our focus on our available products and proprietary reagents."


About MD Biosciences

MD Biosciences provides products and pre-clinical services, which include efficacy testing, mode of action platforms, in vitro analysis, histology and imaging for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of experts to tackle problems and provide solutions. MDB also supplies for purchase by all laboratories many of the products and proprietary reagents used in our research, regardless of whether MDB is contracted as a research organization. This allows our clients to optimize their own research process by selecting steps to be performed by MDB and research to be performed in-house.




###


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: CRO/outsourcing

MD Biosciences Releases Tamm-Horsfall (Uromodulin) ELISA

Posted by Amy Clausen on Jul 6, 2009 2:14:00 PM


MD Biosciences, a global biotechnology company, announces the recent launch of its new Tamm-Horsfall (THP, Uromodulin) ELISA. To date, very few manufactured ELISAs are commercially available for the measurement of THP, causing researchers to spend extra time optimizing and manufacturing their own with the potential for variable results. The MD Biosciences Tamm-Horsfall ELISA kit has been optimized during development to provide precise and reproducible results. Selection of antibody pairs, careful control of microplate coating, formulation of reagents and protocol design along with stringent quality control procedures compile a completed ELISA kit that provides researchers a rapid and easy to use alternative to the do-it-yourself methods.

 

Tamm-Horsfall ELISA Specifications (Catalog # M036020):

Range of Assay: 9.375 – 150 ng/mL

Sensitivity: <5.50 ng/mL

Length of Assay: 2 hours 40 min

Sample Size: 50 uL

Precision: < 12.2 %CV for intra- and inter-assay precision

Cross-Reactivity: Human and canine urine samples

 

Tamm-Horsfall protein (THP, also known as uromodulin) is the most abundant protein found in the urine of mammals. THP is 616 amino acids in length with a molecular weight of 80 kDa, and is synthesized in the thick ascending loop of Henle. While the specific function of THP is unknown, it appears to have a role in the regulation of salt and water excretion by the kidney. Soluble THP has been found to help protect against urinary tract infections of E. coli and P. mirabilis by inhibiting the binding of the bacteria to the epithelial cells of the urinary tract. In addition, it has been suggested that THP may help prevent renal stone formation. Defects in THP are associated with human diseases such as familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease (MCKD2).

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

MD Biosciences Adds Myocardial Infarct Models to its Porfolio

Posted by Amy Clausen on Mar 4, 2009 12:03:00 PM


Wednesday, March 4, 2009, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study of myocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
New models include:
-       Ligation induced acute cardiac infarction
-       Coil-induced acute cardiac infarction
-       Balloon-induced cardiac ischemia reperfusion
-       Multi-focal myocardial infarct
-       Induction of vascular disease

 

These models offer the flexibility of protocol design for monitoring a variety of parameters such as ECG, invasive blood pressure, SpO2, ETCO2, and PPV. Readouts offered include ECG, Echo, Angiography, cardiac MRI and blood tests for relevant parameters such as CPK. All tests are analyzed by expert cardiologists in collaboration with the Heart Institute, Sheba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays. eba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.

About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

 

--------

 

 

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Cardiovascular

MD Biosciences Releases Human Collagen Type I ELISA

Posted by Amy Clausen on Feb 9, 2009 12:10:00 PM


St Paul, MN February 9, 2008MD Biosciences, a global biotechnology company focused in inflammations and neurology research, announces the recent launch of its new Human Type I Collagen (CI) ELISA, Catalog # M036007, for use with cell culture supernates. The ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for a 24 hour blocking incubation found with other commercially available kits. Results are achieved in under 3 hours and are sensitive, accurate and reproducible.


Human Collagen Type I ELISA Kit specifications include:

-        100 uL sample size

-        Dynamic range of 0.062 – 5 ug/mL

-        Sensitivity < 0.35 ug/mL

-        Length of assay < 3 hours

-        Crossreactivity is < 0.1% with Type II and Type IV collagen

Collagen Type I (COL1A1, COL1A2) is the most abundant protein and is found in the skin, connective tissue, tendons, ligaments, cornea, intevertebral disks, scar tissue, and lung. It has been found to be involved in many human diseases such as fibrosis, osteoporosis, cancer and artherosclerosis. It is a fibrillar collagen comprised of 3 polypeptide chains (alpha-chains), which form a unique helical structure. It is a heterotrimer of two a1(I) and one a2(I) chains. Collagen Type I molecules form cross-striated fibrils in the extracellular space, giving the tissues their mechanical strength and providing the major biomechanical scaffold for cell attachment and anchorage of macromolecules. Collagen Type I also interacts with many cells, such as fibroblasts, and with platelets during blood clotting.

 


The addition of the Human Collagen Type I assay enhances the line of collagen-related products offered by MD Biosciences, which include Collagen Type II ELISA; Anti-Collagen Type II ELISAs for IgG; IgG2a and IgG2b isotypes (see http://www.mdbiosciences.com/elisas_assays.html for a list of current ELISAs); Collagen Type II Staining kit, Bovine and Chicken Collagen Type II http://www.mdbiosciences.com/typeIICollagen.html), Collagen Antibodies and ArthritoMab Anti-Collagen Antibody Cocktail (http://www.mdbiosciences.com/ArthritoGenicMonoclonalAntibodyCocktailProduct.html)


About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

MD Biosciences to Showcase Preclinical Capabilities at Neuroscience Conf

Posted by Amy Clausen on Nov 11, 2008 12:15:00 PM


St Paul, MN, November 11, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 – 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson’s Disease, Nociceptive, Neuropathic, Post-operative and Inflammatory Pain.

Multiple Sclerosis:

Multiple sclerosis is a demyelinating disease of the CNS. Due to the clinical and pathological similarities of EAE and MS, EAE has been used as a model for the study of human demyelinating disease and is characterized by a relapsing-remitting disease course with subsequent progressive disability.

  • MBP-induced EAE
  • MOG-induced EAE
  • PLP-induced EAE.

Gliosis:

Gliosis is a proliferation of astrocytes in the central nervous system (CNS) in response to injury which results in scar formation. Astrocytes react to injury by hypertrophy and up-regulation of the glial-fibrillary acidic protein. Gliosis, along with neuronal loss, is a prominent feature of many diseases of the central nervous system.

Parkinson’s Disease:

Parkinon's Disease (PD) is a neurogenerative disorder characterized by reduction in striatial (DA) content caused by the loss of dopaminergenic neurons in the Substantia Nigra part compacta (SNpc) and their proportions to the striatum.

  • Acute MPTP
  • Chronic MPTP
  • 6-OHDA

Pain:
MD Biosciences offers Nociceptive, Neuropathic and Inflammatory Pain models:.

  • Tail Flick
  • Visceral Pain
  • Caspaicin
  • Post-operative pain
  • Chronic Constriction Injury (CCI, Bennett & Xie)
  • Taxol induced Neuropathic Pain
  • Spinal Nerve Ligation (Chung)
  • STZ Diabetic Neuropathy
  • Carrageenan Induced Inflammatory Pain
  • Adjuvant (CFA) induced Inflammatory Pain
  • Arthritic and Monoarthritic Pain.

 

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 ### 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Read More

Topics: Neuro/CNS

MD Biosciences Showcases Preclinical Disease Models at Int’l IRA Conference

Posted by Amy Clausen on Sep 15, 2008 12:20:00 PM


St Paul, Minnesota, September 15, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the Inflammation Research Association (IRA) International Conference, September 21-24, Chantilly, VA. Capabilities featured will be pre-clinical efficacy disease models and research products for drug discovery and research.

MD Biosciences will be hosting a lunch and learn session titled “Discovery of novel therapies for asthma requires suitable and relevant disease models”. Conference attendees are invited to register for this free session upon arrival of the conference. This session will focus on the OVA-induced Asthma model and airway hyperresponsiveness (AHR) as well as the OVA-IgE specific ELISA for measuring OVA specific IgE levels in murine serum samples.

MD Biosciences services that will be featured throughout the conference include the Collagen-Induced Arthritis (CIA), Collagen Antibody-induced Arthritis (CAIA), Adjuvant Induced arthritis (AIA), Monoarthritic Pain, OVA-induced Asthma along with general inflammation assays. Products include collagen related reagents and assays, ArthritoMab™ antibody cocktail, OVA-IgE ELISA, Aggrecan antibodies and T-cell antibodies.

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

###

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

MD Biosciences to Showcase Preclinical Capabilities at World Pain Congress

Posted by Amy Clausen on Aug 12, 2008 12:25:00 PM


Zurich, Switzerland, August 12, 2008 - MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 12th World Congress on Pain (IASP) in Glasgow, Scotland, August 17th - 22nd, 2008. Capabilities included in the showcase are efficacy disease models within Nociceptive, Neuropathic, Post-operative and Inflammatory Pain.


Nociceptive Pain is part of a rapid warning relay instructing the motor neurons of the central nervous system to minimize detected physical harm. Disease models include the Tail Flick Model – used to measure the response to noxious stimuli, the Visceral Pain Model – used to measure the effectiveness of analgesic agents, the Caspaicin model – used to evaluate response mediated by the VR1 pathway, and Post-operative pain models for screening the pathophysiology of hyperalgesia.

Neuropathic Pain is produced by damage to the neurons in the peripheral and central nervous systems. Disease models include the Chronic Constriction Injury (CCI, Bennett & Xie) model - involves inflammation around the nerve, the Taxol induced Neuropathic Pain model – causing peripheral nerve ending injury, the Spinal Nerve Ligation (Chung) Model – nerve ligation between L5 & L6, and the STZ Diabetic Neuropathy model – direct destruction of the nerve associated with high levels of glucose.

Inflammatory Pain is associated with tissue damage and the resulting inflammatory response. Disease models include the Carrageenan Induced Inflammatory Pain, Adjuvant (CFA) induced Inflammatory Pain and Arthritic Pain.

Additional models are offered as requested along with end-point readouts such as biomarker analysis, histology, and gene expression analysis. MD Biosciences will also be showcasing its capabilities at additional events this fall including the Inflammations Research Association (IRA) in September and the American College of Rheumatology (ACR) in October.

 

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

Read More

New Mouse anti-Collagen Type II (anti-CII) ELISAs.

Posted by Amy Clausen on Mar 3, 2008 12:27:00 PM


St Paul, MN March 4, 2008 – MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new line of Mouse anti-Collagen Type II (anti-mouse CII) ELISAs. The new Mouse anti-collagen CII ELISAs allow you to measure antibodies generated against the species of collagen used in the induction of arthritis in mice (bovine, human, mouse, rat, chicken, porcine). IgG and two subclasses (IgG2a and IgG2b) are now available as ready-to-use ELISAs that provide fast, accurate and reliable results.

 

The Collagen-induced arthritis (CIA) model is one of the most widely used models for the study of RA. Collagen type II (CII) in adjuvant is used to induce arthritis by triggering autoreactive B cells, which play an important role in the development of arthritis. This B cell response to CII is strictly T cell dependent, where the B cells predominantly switch isotype to IgG.

 

The anti-Type II Collagen ELISAs offer many improvements over other commercially available anti-Collagen Type II ELISAs. The kits come ready to use eliminating any plate coating or blocking as well as eliminates lengthy sample incubations. The assays can be completed in under 3 hours using only 100 uL of sample. Performance characteristics such as precision CVs less than 10%, recovery and linearity averaging at 82% and 102% respectively, and cross-reactivity with other collagen types of less than 0.004% provide reliable, accurate and sensitive assays for the detection mouse Collagen Type II antibodies.

 

The addition of these assays enhances the arthritis products and services currently offered by MD Biosciences. Research products include assays for measuring type II collagen and antibodies, assay for staining type II collagen, induction reagents such as collagen, adjuvant and ArthritoMabÒ antibody cocktail. Pre-clinical services include collagen-induced arthritis (CIA), Antibody induced arthritis (CAIA), Adjuvant Induced Arthritis as well as in vitro disease models providing the researcher a well-rounded approach for using MD Biosciences products in-house as well as outsourcing other areas of their drug discovery platform.

 

 

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

 

 

Read More

Topics: Research Products

MD Biosciences Releases Mouse OVA-IgE ELISA

Posted by Amy Clausen on Aug 3, 2007 12:30:00 PM

MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new Mouse OVA-IgE ELISA. The OVA-IgE ELISA offers researchers sensitive, reproducible, accurate and reliable results for the measurement of OVA specific IgE in mouse serum and cell culture supernate samples. The kit is ready-to-use with all necessary reagents and can be completed in under 2.5 hours, requires small sample sizes and measures levels down to 7.8 ng/mL with a sensitivity of less than 3.8 ng/mL.

Ovalbumin is widely used in inducing an allergic response in mouse models of allergic asthma. Through T cell and B cell signalling, IgE production is stimulated and released into the bloodstream where IgE attaches to cells such as mast cells and basophils. These cells are then activated after the IgE is cross-linked with antigen, initiating the allergic cascade.

In addition the Mouse OVA-IgE ELISA, MD Biosciences also offers other reagents such as T1/ST2 antibodies, in vitro assay services and efficacy disease models for the study of allergic asthma.

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

###

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Research Products

High ArthritoMabTM Antibody Cocktail Activity |18-day RA Model Balb/c Mice

Posted by Amy Clausen on Apr 3, 2007 12:33:00 PM

MD Biosciences releases histology results from an 18-day model of arthritis induced using the ArthritoMab(TM) cocktail of arthritogenic antibodies in Balb/c mice. Results show significant histological changes in the joint of the arthritis group as compared to the normal control group after just 18 days, providing researchers valuable data quickly compared to the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results.

Results show significant histological changes in the joint of the arthritis group as compared to the normal control group after just 18 days, providing researchers valuable data quickly compared to the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results. Figures 1-3 show the effectiveness of the arthritogenic antibodies, with mean histology scores and staining sections indicating the degree of erosion, hyperplasia and infiltration in the joint of the arthritis group as compared to the control group.

 

ArthritoMab histology

 

 

The ArthritoMabTM Arthritogenic Antibody Cocktail is comprised of 4 monoclonal antibodies to collagen type II (CII) that have been chosen for their epitope specificity. An antibody response to certain epitopes is better associated with arthritis than a response to other epitopes. In the CIA model, the antibody response correlated with arthritis was mainly associated with binding to the epitopes C1, J1, and U1. The ArthritoMabTM monoclonal antibodies were selected to bind to the epitopes C1, J1, U1 and D3 - which are spread over the entire CII region (fragments CB8, CB10 and CB11) encouraging better immune complex formation on the cartilage surface for the initiation of arthritis. The antibody-induced arthritis model using the ArthritoMabTM Arthritogenic Antibody cocktail is a rapid alternative the CIA model.

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Inflammation, Research Products